Literature DB >> 6215893

Piperacillin pharmacokinetics in pediatric patients.

C B Wilson, J R Koup, K E Opheim, L A Adelman, J Levy, T L Stull, C Clausen, A L Smith.   

Abstract

The pharmacokinetics of piperacillin were studied in 15 pediatric patients (age range, 3.3 to 14.3 years). Piperacillin was administered in a dosage of 1.5 +/- 0.4 g/m2 (mean +/- standard deviation) every 4 to 6 h. Peak serum concentrations ranged from 69 to 354 micrograms/ml. The mean elimination half-life was 37.0 +/- 13.3 min, which is shorter than that observed in most adults with normal renal function. The mean elimination half-life in three patients with renal impairment was 60.1 +/- 12.4 min, and the mean ratio of renal clearance to total clearance was 0.57. These results suggest a significant nonrenal elimination of piperacillin. Based on these data, a dosage of 1.5 g/m2 given as a 30-min infusion every 4 h is suggested for children with normal renal function. For patients with renal impairment, the daily dosage could be calculated as follows: corrected dose = normal dose x (0.35 + [0.65 x (ClCr/0.06)]), where ClCr is the creatinine clearance expressed as liters per minute per square meter.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215893      PMCID: PMC183763          DOI: 10.1128/AAC.22.3.442

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Carbenicillin therapy in patients with normal and impaired renal function.

Authors:  D L Latos; C S Bryan; W J Stone
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

2.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Pharmacokinetics of ticarcillin in patients with abnormal renal function.

Authors:  M F Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

4.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

5.  Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis.

Authors:  A S Prince; H C Neu
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

6.  Susceptibility of gram-negative aerobic bacilli resistant to carbenicillin in a general hospital to piperacillin and ticarcillin.

Authors:  J E McGowan; P M Terry
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

7.  Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

9.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

10.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

View more
  13 in total

1.  Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

Authors:  F Rusconi; B M Assael; A Boccazzi; R Colombo; R M Crossignani; L Garlaschi; L Rancilio
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 2.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 3.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 4.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

6.  Piperacillin in early neonatal infection.

Authors:  M Placzek; A Whitelaw; S Want; M Sahathevan; J Darrell
Journal:  Arch Dis Child       Date:  1983-12       Impact factor: 3.791

7.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.

Authors:  G L Drusano; C de Jongh; K Newman; J Joshi; R Wharton; M R Moody; S C Schimpff
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

9.  Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen
Journal:  AAPS J       Date:  2016-01-22       Impact factor: 4.009

Review 10.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.